Highlights and Quick Summary
- SG&A Expenses for the quarter ending September 30, 2022 was $15.1 Million (a -0.79% decrease compared to previous quarter)
- Year-over-year quarterly SG&A Expenses increased by 11.48%
- Annual SG&A Expenses for 2021 was $50.5 Million (a 44.93% increase from previous year)
- Annual SG&A Expenses for 2020 was $34.9 Million (a 13.77% increase from previous year)
- Annual SG&A Expenses for 2019 was $30.6 Million (a 18.29% increase from previous year)
- Twelve month SG&A Expenses ending September 30, 2022 was $58.4 Million (a 2.65% increase compared to previous quarter)
- Twelve month trailing SG&A Expenses increased by 15.59% year-over-year
Trailing SG&A Expenses for the last four month:
| 30 Sep '22 | 30 Jun '22 | 31 Mar '22 | 31 Dec '21 |
|---|---|---|---|
| $58.4 Million | $56.9 Million | $53.1 Million | $50.5 Million |
Visit stockrow.com/BDSX
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical SG&A Expenses of Biodesix, Inc.
Most recent SG&A Expensesof BDSX including historical data for past 10 years.Interactive Chart of SG&A Expenses of Biodesix, Inc.
Biodesix, Inc. SG&A Expenses for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | – | $15.11 | $15.24 | $14.49 | – |
| 2021 | $13.56 | $13.61 | $11.43 | $11.93 | $50.52 |
| 2020 | $12.06 | $7.88 | $6.83 | $8.08 | $34.86 |
| 2019 | – | – | $6.56 | $8.21 | $30.64 |
| 2018 | – | – | – | – | $25.9 |
Business Profile of Biodesix, Inc.
Sector: Healthcare
Industry: Diagnostics & Research